scholarly journals The neuro-inflammasome in Alzheimer’s disease and cerebral stroke

2021 ◽  
Author(s):  
Jong-hoon Lee
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Side Effects ◽  
Neuropsychiatric Symptoms ◽  
Clinical Staging ◽  
Cerebral Stroke ◽  
Diaminodiphenyl Sulfone

Aim/Background: This Review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuro-inflammasome competitor.Methods: We monitored AD’s progression through Numeric Clinical staging (NCS) with a new biomarker. NCS was determined by the AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD drugs (AAD) as a biomarker (D). We also monitored the function of DDS for Stroke in a no-intake emergency state.Results: By introducing (D), AD's progression was monitored through NCS staging; AAD side effects and neuropsychiatric symptoms were distinguished. DDS was stopped in the Stroke with NCS 6 by AAD, and it rapidly proceeds to cerebral infarct.Conclusions: AADs can occasionally exacerbate AD and Stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and Stroke. We clinically confirmed the role of DDS as a neuro-inflammasome competitor after Stroke. DDS keep neuronal survivals within 24 - 55 hours in the Seoul cohort.

scholarly journals The neuro-inflammasome in Alzheimer’s disease and cerebral Stroke

2021 ◽  
Author(s):  
JONG HOON LEE ◽  
Chul Joong Lee ◽  
Jungwuk Park ◽  
So Jeong Lee ◽  
Su-hee Choi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Side Effects ◽  
Neuropsychiatric Symptoms ◽  
Clinical Staging ◽  
Cerebral Stroke ◽  
Diaminodiphenyl Sulfone

Abstract Aim/Background: This Review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuro-inflammasome competitor.Methods: We monitored AD’s progression through Numeric Clinical staging (NCS) with a new biomarker. NCS was determined by the AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD drugs (AAD) as a biomarker (D). We also monitored the function of DDS for Stroke in a no-intake emergency state.Results: By introducing (D), AD's progression was monitored through NCS staging; AAD side effects and neuropsychiatric symptoms were distinguished. DDS was stopped in the Stroke with NCS 6 by AAD, and it rapidly proceeds to cerebral infarct.Conclusions: AADs can occasionally exacerbate AD and Stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and Stroke. We clinically confirmed the role of DDS as a neuro-inflammasome competitor after Stroke. DDS keep neuronal survivals within 24 - 55 hours in the Seoul cohort.

scholarly journals The Neuroinflammasome in Alzheimer’s Disease and Cerebral Stroke

2021 ◽  
pp. 159-167
Author(s):  
Jong-hoon Lee ◽  
Chul Joong Lee ◽  
Jungwuk Park ◽  
So Jeong Lee ◽  
Su-hee Choi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Neuropsychiatric Symptoms ◽  
Clinical Staging ◽  
Cerebral Stroke ◽  
Study Cohort ◽  
Diaminodiphenyl Sulfone

<b><i>Aim/Background:</i></b> This review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor. <b><i>Methods:</i></b> We monitored AD’s progression through numeric clinical staging (NCS) with a new biomarker. NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker. We also monitored the function of DDS for stroke in a no-intake emergency state. <b><i>Results:</i></b> By introducing (D), AD’s progression was monitored through NCS staging. AAD side effects and neuropsychiatric symptoms were identified. DDS was stopped in patients with stroke with NCS 6 caused by AAD, and it rapidly proceeded to cerebral infarct. <b><i>Conclusions:</i></b> AAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24–55 h in the Seoul Study cohort.

scholarly journals The neuro-inflammasome in Alzheimer’s disease and cerebral stroke

2020 ◽  
Author(s):  
Jong-hoon Lee
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Side Effects ◽  
Psychiatric Symptoms ◽  
Neuropsychiatric Symptoms ◽  
Clinical Staging ◽  
Cerebral Stroke ◽  
Study Results ◽  
Before And After ◽  
Neuro Inflammation

Aim/Background: This study investigated patients with Alzheimer’s disease (AD) who were treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuro-inflammasome competitor according to the 2018 'NIA-AA Research Framework' to differentiate neuro-psychiatric symptoms from drug side effects. Methods: According to the diagnostic criteria of AD, the Seoul study analysed AD and anti-AD drugs (AADs) in the EDI database of the Sorokdo National Hospital archived from January 2005 to June 2020 and searched using the ICD-9 and 10 codes. Numeric clinical staging (NCS) was determined by managing the AD symptoms and neuropsychiatric symptoms caused by AADs with a new biomarker, (D). We report related cases of cerebral infarction and the function of DDS as a neuro-inflammasome competitor in the Seoul study. Results: DDS acts as a neuro-inflammasome competitor; this effect can be inferred by comparing the prevalence of AD in patients who have been prescribed DDS and those who have not. By the introduction of (D), the progression of AD was monitored through NCS staging; AAD side effects and neuropsychiatric symptoms were distinguished and treated with DDS. AD can occasionally be exacerbated by AADs, and mild cognitive impairment can be alleviated by DDS. We clinically confirmed the role of DDS as a neuro-inflammasome competitor before and after cerebral infarcts in the Seoul study. Conclusions: DDS acts as a blocker of canonical/non-canonical ubiquitylation; NLRP3 inflammasome formation; Higgins’ cascade; and iron-rich, strongly magnetic nanoparticles released by the splitting of red blood cells. (D) can be used to guide the prevention and treatment of AD with DDS. This study demonstrates the use of NCS and neuro-inflammation treatment as a preventive and therapeutic method for AD.

Mild cognitive impairment in primary care: a clinical review

2018 ◽  
Vol 94 (1117) ◽  
pp. 647-652 ◽  
Author(s):  
Georges Assaf ◽  
Maria Tanielian
Keyword(s):  
Alzheimer’S Disease ◽  
Primary Care ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Clinical Review ◽  
Primary Care Physicians ◽  
Early Recognition ◽  
Neuropsychiatric Symptoms ◽  
Evidenced Based

Dementia is projected to become a global health priority but often not diagnosed in its earlier preclinical stage which is mild cognitive impairment (MCI). MCI is generally referred as a transition state between normal cognition and Alzheimer’s disease. Primary care physicians play an important role in its early diagnosis and identification of patients most likely to progress to Alzheimer’s disease while offering evidenced-based interventions that may reverse or halt the progression to further cognitive impairment. The aim of this review is to introduce the concept of MCI in primary care through a case-based clinical review. We discuss the case of a patient with MCI and provide an evidence-based framework for assessment, early recognition and management of MCI while addressing associated risk factors, neuropsychiatric symptoms and prognosis.

scholarly journals The Role of Dietary and Lifestyle Factors in Maintaining Cognitive Health

2017 ◽  
Vol 12 (4) ◽  
pp. 268-285 ◽  
Author(s):  
Nathalie E. Marchand ◽  
Majken K. Jensen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Lower Risk ◽  
Controlled Trial ◽  
Cognitive Health ◽  
Healthy Diets ◽  
Global Population

Concern over loss of cognitive function, including descent into Alzheimer’s disease or dementia, grips a growing percentage of men and women worldwide as the global population ages. Many studies, though not all, suggest that maintaining cognitive health, as well as slowing and even preventing cognitive decline, dementia, and Alzheimer’s disease, can be achieved by consuming healthy diets over a long enough period of time. This appears to be the case even for those who initiated dietary changes later in life, as evidenced by an intervention study assessing consumption of a healthy diet among those who were >50 years of age. All such diets share the common traits of being rich in fruits, vegetables, whole grains, and fish or seafood, while also being low in red meat and sweets. A Mediterranean-style diet shares these characteristics and has been associated with an estimated 40% lower risk of cognitive impairment, including mild cognitive impairment, dementia, and Alzheimer’s disease in prospective studies, in addition to being associated with both a 65% lower risk of mild cognitive impairment and improved cognitive performance in a notable randomized controlled trial.

Depressive Neuropsychiatric Symptoms and Mild Cognitive Impairment as Part of the Diabetes Mellitus/Alzheimer's Disease Link

2021 ◽  
Author(s):  
Karla Aketzalli Hernández-Contreras ◽  
Jorge Antonio Martínez-Díaz ◽  
María Elena Hernández-Aguilar ◽  
Deissy Herrera-Covarrubias ◽  
Fausto Rojas-Durán ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Neuropsychiatric Symptoms
Sign in / Sign up

Export Citation Format

Share Document